Bharti Airtel Ltd

Bharti Airtel Ltd is world’s leading provider of telecommunication services with presence in 16 countries across Asia and Africa. It had over 444 million customers across its operations at the end of September 2018.

Outlook and Valuation: We believe near-term challenges will persist in India’s mobility segment considering Reliance Jio’s aggressive push to grab subscriber market share. Though ARPU is expected to remain under pressure in the near term due to downtrading of subscribers, it is expected to recover in the medium to long term considering ongoing consolidation in the sector and industry repair, which will help Airtel drive market share gains. We believe deleveraging of balance sheet with USD1.25bn equity infusion in the Africa business will help company meet rising investment in network. Further, higher data consumption driven by increasing smartphone penetration & investments in up-gradation and expansion of network towers and increase in content consumption will drive next phase of growth for Bharti Airtel. Hence, we recommend ‘BUY’ rating on the stock with a TP of Rs. 329 based on SOTP methodology.

MORE WILL UPDATE SOON !!

Comments

Buy Axis Bank for target of Rs 725

Stock can be bought at current levels and on dips to Rs 620 with stop loss below Rs 600 for target of Rs 725 levels. Axis Bank has formed symmetrical triangle pattern on weekly chart and trading in a range of Rs 650 and Rs 350 odd levels for almost three years now. On daily chart stock has seen sharp bounce back from 200-day moving average. For last couple stock has been facing at Rs 640-650 zone but forming higher lows. Thus, forming bullish ascending triangle pattern on daily chart. Relative strength index and Stochastic have given positive crossover with their respective averages on daily chart. On monthly chart ADX ine indicator of trend strength is moving up from neutral level of 20 suggesting strength emerging long term trend. Thus, stock can be bought at current levels and on dips to Rs 620 with stop loss below Rs 600 for target of Rs 725 levels. MORE WILL UPDATE SOON!!

Income Tax Deductions List FY 2018-19 | List of important Income Tax Exemptions for AY 2019-20

Budget 2018-19 & the Finance Bill 2018 have been tabled in Parliament. The Income Tax Slab rates have been kept unchanged by the Finance Minister for the Financial Year 2018-19 (Assessment Year 2019-2020) . Tax planning is an important part of a financial plan. Whether you are a salaried individual, a professional or a businessman, you can save taxes to certain extent through proper tax planning. The Indian Income Tax act allows for certain Tax Deductions / Tax Exemptions which can be claimed to save tax. You can subtract tax deductions from your Gross Income and your taxable income gets reduced to that extent. In this post, let us go through the Income Tax Deductions List FY 2018-19 . I hope you find this list useful and helps in planning your taxes well in advance. Income Tax Deductions List FY 2018-19 / AY 2019-20 (Chapter VI-A deductions list) Section 80c The maximum tax exemption limit under Section 80C has been retained as Rs 1.5...

Buy Ajanta Pharma

We believe Ajanta Pharma is in a sweet spot and this valuation justify for the company and have a buy rating. USFDA cleared Ajanta Pharma’s Dahej facility which was built with a capex of Rs 500 crore. While, the first block of its Guwahati facility which is dedicated for derma products started production during FY18, while the second phase’s expansion is underway and may see stabilisation by October 2018, company expects a contribution will start coming in FY20. Apart from ramping up facilities and increasing capex company has also plans to acquire brands in India and abroad to supplement growth. In India, most of its core brands have stabilised and are showing growth. Management also aims to strengthen its domestic presence. Apart from spending over Rs 800 crore in the last three years, it further plans to do capex of Rs 500 crore over a couple of years. Most of this capex will be spent on Guwahati facility’s second phase. We believe Ajanta Pharma is in a sweet spo...

IndianMarketPulse-Investment Advice

Search This Blog